Long-term survival following molecular-targeted therapy for intramedullary non-small-cell lung cancer metastasis
Although the prognosis for ICSM is generally poor, molecular-targeted therapies, such as alectinib, as administered in this case, may provide long-term survival for patients with ALK-positive NSCLC tumors.
Authors
- Manabu Minami (ORCID: https://orcid.org/0000-0002-6750-2924)
- Ryo Kanematsu (ORCID: https://orcid.org/0000-0002-6390-2330)
- Koichi Mitsuya (ORCID: https://orcid.org/0000-0001-8956-5427)
- Toshiyuki Takahashi (ORCID: https://orcid.org/0000-0002-8783-3528)
- Junya Hanakita (ORCID: https://orcid.org/0000-0002-5984-3147)
Institutions
- Shizuoka Cancer Center (JP)
- Fujieda Municipal General Hospital (JP)
Publication Details
- Journal
- Surgical Neurology International
- Published
- 2024-08-30
- DOI
- https://doi.org/10.25259/sni_603_2024
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00